EUVIMEDEUVIMED entdecken
Crossref

Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study

Yinghong Zhai iD, Fangyuan Hu, Borui Zhu, Jinfang Xu, Xiaojing Guo, Wentao Shi, Xiang Zhou, Yi Zheng, Xiao Xu, Xiaofei Ye, Jia He iD, Feng Xu

Immunotherapy · 2023

DOI: 10.2217/imt-2022-0145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy, 2023. Verfasst von Yinghong Zhai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, School of Medicine, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, 200011, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System, Military Key Discipline Construction Project, The Shanghai Municipal Commission of Health and Family Planning Fund for Excellent Young Scholars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Comprehensively characterize the cardiotoxicity of CD19-directed chimeric antigen receptor T-cell (CAR-T) products. Materials & methods: Data between 2017 and 2021 in the US FDA's Adverse Event Reporting System database were utilized. Disproportionality was measured using reporting odds ratio and information component. Hierarchical clustering analysis was performed to explore the relationships among cardiac events.

Results

Tisagenlecleucel exhibited the highest percentage of death (53.24%) and life-threatening (13.39%) outcomes. Axicabtagene ciloleucel and tisagenlecleucel were equal in the number of positive signals (n = 15), while the former had excessive reporting of several cardiac events versus the latter, such as atrial fibrillation, cardiomyopathy, cardiorenal syndrome and sinus bradycardia.

Conclusion

Several cardiac risks should be considered for CAR-T treatment and these events might vary in frequency and severity following different CAR-T agents. Chimeric antigen receptor T-cell (CAR-T) therapy is effective in a wide spectrum of malignancies. However, the complete cardiotoxicity profile associated with this new treatment has not been characterized. This study systematically analyzed the reported cardiac events of four approved CAR-T agents using the US FDA's Adverse Event Reporting System database. It indicated that the type of cardiac events was broad and overlapped a lot with cytokine release syndrome. Pre-therapy assessment, intensive monitoring and appropriate intervention were critical to reduce the level of cardiac damage or the rate of mortality in patients receiving CAR-T.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHumansPharmacovigilanceImmunotherapy, AdoptiveReceptors, Antigen, T-CellAntigens, CD19Adaptor Proteins, Signal TransducingCardiotoxicityCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

FAERS databasecardiotoxicitychimeric antigen receptor T celldisproportionality analysisinformation componentreporting odds ratio

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-CellAntigens, CD19Adaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Clinical Research Center, School of Medicine, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, 200011, China.
  • Department of Medical Service, Naval Hospital of Eastern theater, Zhejiang Zhoushan, 316000, China.
  • Department of Health Statistics, Second Military Medical University, Shanghai, 200433, China.
  • Tongji University School of Medicine, 1239 Siping Road, Yangpu District, Shanghai, 200092, China.

ORCID-Profile: Yinghong Zhai, Jia He

Förderung

  • Three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System
  • Military Key Discipline Construction Project
  • The Shanghai Municipal Commission of Health and Family Planning Fund for Excellent Young Scholars
  • The Excellent Young Scholars of public health in Shanghai
  • The National Nature Science Foundation of China
  • The Leading Talents of Public Health in Shanghai

Zitieren

APA

Zhai, Y., Hu, F., Zhu, B., Xu, J., Guo, X., Shi, W., Zhou, X., Zheng, Y., Xu, X., Ye, X., He, J., & Xu, F. (2023). Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study. Immunotherapy. https://doi.org/10.2217/imt-2022-0145

Vancouver

Zhai Y, Hu F, Zhu B, Xu J, Guo X, Shi W, et al. Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study. Immunotherapy. 2023. doi:10.2217/imt-2022-0145

BibTeX
@article{Zhai2023,
  author = {Zhai, Yinghong and Hu, Fangyuan and Zhu, Borui and Xu, Jinfang and Guo, Xiaojing and Shi, Wentao and Zhou, Xiang and Zheng, Yi and Xu, Xiao and Ye, Xiaofei and He, Jia and Xu, Feng},
  title = {Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study},
  journal = {Immunotherapy},
  year = {2023},
  doi = {10.2217/imt-2022-0145}
}
Kostenlos starten →